2. Search Result
Search Result
Results for "

Neuropsychiatric disorders

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

2

Bibliotecas de Screening

2

Peptides

2

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-148104
    ACSS2-IN-2
    1 Publications Verification

    		 Acetyl-CoA synthetase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .
    ACSS2-IN-2
  • HY-B1395
    Mecamylamine hydrochloride
    5 Publications Verification

    		 nAChR Histamine Receptor Cardiovascular Disease Neurological Disease
    Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .
    Mecamylamine hydrochloride
  • HY-117516
    SR10067

    		REV-ERB Neurological Disease Metabolic Disease
    SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .
    SR10067
  • HY-103213
    JP1302 dihydrochloride
    2 Publications Verification

    		 Adrenergic Receptor Neurological Disease Endocrinology
    JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .
    JP1302 dihydrochloride
  • HY-159829
    Direclidine

    NBI-1117568; HTL-0016878

    		 mAChR Neurological Disease
    Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .
    Direclidine
  • HY-19348
    Pimelic Diphenylamide 106
    5 Publications Verification

    RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII

    		 HDAC Monoamine Transporter Neurological Disease Cancer
    Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC50 values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .
    Pimelic Diphenylamide 106
  • HY-157521
    AANAT-IN-1

    		Acyltransferase Neurological Disease Metabolic Disease
    AANAT-IN-1 is an arylalkylamine N-acetyltransferase (AANAT) inhibitor with a sheep AANAT IC50 of 9.9 μM. AANAT-IN-1 binds to the active site of sheep AANAT, interacting with amino acid residues via hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridges, inhibiting the enzyme's catalytic activity. AANAT-IN-1 can be used for the researches of circadian rhythm-associated neuropsychiatric conditions, seasonal affective disorder, and other diseases associated with abnormally elevated melatonin levels .
    AANAT-IN-1
  • HY-103493
    TAK-915

    		Phosphodiesterase (PDE) Neurological Disease
    TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .
    TAK-915
  • HY-14826
    Tilivapram

    AVE8112

    		 Phosphodiesterase (PDE) Neurological Disease
    Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .
    Tilivapram
  • HY-116483
    MPX-007

    		iGluR Neurological Disease
    MPX-007 is a GluN2A antagonist (IC50: 27 nM). MPX-007 is a tools to probe GluN2A physiology, and to study neuropsychiatric and developmental disorders .
    MPX-007
  • HY-103213A
    JP1302
    2 Publications Verification

    		 Adrenergic Receptor Neurological Disease
    JP1302 is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research .
    JP1302
  • HY-148939
    MPX-004

    		iGluR Neurological Disease
    MPX-004 is a potent GluN2A antagonist. MPX-004 inhibits GluN2A-containing NMDA receptors expressed in HEK cells with an IC50 of 79 nM. MPX-004 has no inhibitory effect on GluN2B or GluN2D receptor-mediated responses. MPX-004 has the potential for neuropsychiatric and developmental disorders research .
    MPX-004
  • HY-163671
    PW0729

    		GPR52 Neurological Disease
    PW0729 (compound 15b) is an orphan GPR52 agonist with potential applications in GPR52 activation, signaling bias, and neuropsychiatric and neurological disorders. The brain exposure characteristics of PW0729 need to be further optimized .
    PW0729
  • HY-14840A
    (R)-Phenylpiracetam

    MRZ 9547

    		 Dopamine Transporter Neurological Disease Inflammation/Immunology
    (R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (Ki: 14.8 μM; IC50: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .
    (R)-Phenylpiracetam
  • HY-172995
    RS130-180

    		5-HT Receptor Neurological Disease
    RS130-180 is a selective β-arrestin-biased agonist targeting the serotonin 2A receptor (5-HT2aR). RS130-180 is promising for research of neuropsychiatric disorders such as depression .
    RS130-180
  • HY-P1386
    D15

    Dynamin II (828–842)

    		 iGluR Neurological Disease
    D15, a peptide with 15 aa segment of dynamin, is an AMPAR endocytosis inhibitor. D15 blocks the interaction of dynamin with amphiphysin 1 and 2. D15 significantly increases AMPAR excitatory postsynaptic potential (EPSC) amplitude of medium spiny neurons (MSNs) in Sapap3 KO mice. D15 can be used for neuropsychiatric disorder research .
    D15
  • HY-B1395A
    Mecamylamine

    		nAChR Histamine Receptor Cardiovascular Disease Neurological Disease
    Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .
    Mecamylamine
  • HY-176287
    ARN25657

    		Dopamine Receptor GSK-3 PKA P-glycoprotein Neurological Disease
    ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC50 = 15.2 nM, Ki =1.5 nM) and potent GSK-3β inhibitor activity (IC50 = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .
    ARN25657
  • HY-175504
    MLS6357

    		Dopamine Receptor PERK Neurological Disease
    MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC50s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC50 > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .
    MLS6357
  • HY-116430
    (S)-SKF-77434

    (S)-APB

    		 Dopamine Receptor Drug Isomer Neurological Disease
    (S)-SKF-77434 (Compound 11) ((S)-APB) is an enantiomer of SKF-77434 (HY-103417). (S)-SKF-77434 shows an affinity for the D1 receptor with an IC50 of 2800 nM. (S)-SKF-77434 can be used in the research of neuropsychiatric disorders .
    (S)-SKF-77434
  • HY-172981
    CTW0404

    		5-HT Receptor Neurological Disease
    CTW0404 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0404 is promising for research of neuropsychiatric disorders .
    CTW0404
  • HY-172982
    CTW0419

    		5-HT Receptor Neurological Disease
    CTW0419 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0419 is promising for research of neuropsychiatric disorders .
    CTW0419
  • HY-19130
    BW-534U87

    		Adenosine Receptor Neurological Disease
    BW-534U87 is an orally active adenosine A1 receptor agonist and competitive adenosine deaminase (ADA) inhibitor (Ki=7 μM). BW-534U87 elevates brain adenosine levels and suppresses epileptiform activity. BW-534U87 demonstrate anticonvulsant efficacy in animal seizure models. BW-534U87 is promising for research of epilepsy and adenosine-related neuropsychiatric disorders .
    BW-534U87
  • HY-P5756
    CSD-CH2(1,8)-NH2

    		Opioid Receptor Neurological Disease
    CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (Ki: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .
    CSD-CH2(1,8)-NH2
  • HY-106949
    Tazomeline

    		mAChR Neurological Disease
    Tazomeline is a selective M1 muscarinic receptor agonist. Tazomeline inhibits twitch height in rabbit vas deferens(IC50= 0.001 nM). Tazomeline can be used for research of neuropsychiatric disorders .
    Tazomeline
  • HY-176505
    NOP antagonist 1

    		Opioid Receptor Neurological Disease
    NOP antagonist 1 (Compound (-)-31) is a nociceptin opioid peptide (NOP) antagonist with a Kb of 8.65  nM. NOP antagonist 1 can be used for neuropsychiatric disorders research .
    NOP antagonist 1
  • HY-171981
    VU6002703

    		mAChR Neurological Disease
    VU6002703 (Compound 17) is a BBB-penetrable M4 mAChR positive allosteric modulator (PAM) with an EC50 of 0.6  μM for hM4. VU6002703 can be used for neuropsychiatric and rare genetic CNS disorders research .
    VU6002703
  • HY-169163
    BChE-IN-36

    		Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .
    BChE-IN-36
  • HY-177278
    SST1 receptor antagonist-1

    		Somatostatin Receptor Neurological Disease Endocrinology Cancer
    SST1 receptor antagonist-1 (Compound 23) is a selective Somatostatin receptor 1 (SST1) antagonist with pKds of 9.11 and 8.79 for rSST1 and hSST1, respectively. SST1 receptor antagonist-1 can be used for retinal and endocrine dysfunctions, cancer and neuropsychiatric disorders research .
    SST1 receptor antagonist-1
  • HY-103213R
    JP1302 dihydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Neurological Disease Endocrinology
    JP1302 dihydrochloride (Standard) is the analytical standard of JP1302 dihydrochloride. This product is intended for research and analytical applications. JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .
    JP1302 dihydrochloride (Standard)
  • HY-B1395S
    Mecamylamine-d3 hydrochloride

    		Isotope-Labeled Compounds nAChR Neurological Disease
    Mecamylamine-d3 hydrochloride is the deuterium labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier .
    Mecamylamine-d3 hydrochloride
  • HY-14856
    Atagabalin

    PD 0200390

    		 GABA Receptor Neurological Disease
    Atagabalin (PD 0200390) is a selective GABA (gamma-aminobutyric acid) receptor agonist with antianxiety and sedative effects. Atagabalin enhances the activity of the GABA receptor by binding to the α2δ subunit of the GABA receptor, thereby increasing the GABA mediated inhibition. This enhancement results in reduced excitability of neurons, helping to reduce anxiety and improve sleep. Atagabalin can be used to study neuropsychiatric disorders, anxiety or sleep disorders .
    Atagabalin
  • HY-E70395
    Prolyl endopeptidase

    PE; PEP

    		 Biochemical Assay Reagents Neurological Disease
    Prolyl Endopeptidase, highly active in brain and other tissues, catabolizes proline-containing peptides such as substance P, neurotensin, luteinizing hormone-releasing hormone, thyrotropin releasing hormone, bradykinin and angiotensin II. Prolyl Endopeptidase can be used for study of neuropsychiatric diseases such as stress disorder, depression, and schizophrenia .
    Prolyl endopeptidase
  • HY-128584
    VU6005806

    AZN-00016130

    		 mAChR Neurological Disease
    VU6005806 (AZN-00016130) is a potent muscarnic acethylcholine receptor subtype 4 (M4) positive allosteric modulator (PAM), with EC50s of 94 nM, 28 nM, 87 nM and 68 nM for human, rat, dog and cyno M4, respectively. Used in the research of neuropsychiatric disorders .
    VU6005806
  • HY-B1395R
    Mecamylamine hydrochloride (Standard)

    		Reference Standards nAChR Histamine Receptor Cardiovascular Disease Neurological Disease
    Mecamylamine (hydrochloride) (Standard) is the analytical standard of Mecamylamine (hydrochloride). This product is intended for research and analytical applications. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .
    Mecamylamine hydrochloride (Standard)
  • HY-176405
    σ1R-IN-1

    		Sigma Receptor Neurological Disease
    σ1R-IN-1 ((R,R)-1a) is a potent σ-1R inhibitor with an IC50 of 110 nM. σ1R-IN-1 is promising for research of neuropsychiatric disorders .
    σ1R-IN-1
  • HY-149481
    D4R agonist-1

    		Dopamine Receptor Neurological Disease
    D4R agonist-1 (Compound 16f) is a D4R partial agonist (Ki: 2.2 nM). D4R agonist-1 is metabolically stable in rat and human liver microsomes. D4R agonist-1 can be used for research of neuropsychiatric disorders .
    D4R agonist-1
  • HY-B1395S1
    Mecamylamine hydrochloride-13C4,15N

    		Isotope-Labeled Compounds nAChR Neurological Disease
    Mecamylamine (hydrochloride)- 13C4, 15N is the 13C-labeled and 15N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier .
    Mecamylamine hydrochloride-13C4,15N
  • HY-110010
    Nafadotride

    		Dopamine Receptor Neurological Disease
    Nafadotride is a dopamine D3 receptor antagonist. Nafadotrode regulates dopamine signaling primarily by antagonizing dopamine D3 receptors. The dopamine D3 receptor plays an important role in regulating emotion, motivation, reward, and certain motor functions. By blocking these receptors, Nafadotrode may affect neurotransmission processes associated with these functions. Nafadotrode can be used to explore the role of dopamine D3 receptors in various behavioral and neuropsychiatric disorders .
    Nafadotride
  • HY-175505
    Dopamine D3 receptor antagonist-3

    		Dopamine Receptor Neurological Disease
    Dopamine D3 receptor antagonist-3 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist that can cross the blood-brain barrier. Dopamine D3 receptor antagonist-3 exhibits antagonist activity in the D3R-mediated β-arrestin recruitment assay with an IC50 and a Kd of 2.5 μM and 0.49 μM. amine D3 receptor antagonist-3 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 0.34 μM. Dopamine D3 receptor antagonist-3 can be used for the study of neuropsychiatric disorders, including substance use disorder .
    Dopamine D3 receptor antagonist-3
  • HY-176717
    5-HT1AR agonist 3

    		5-HT Receptor Neurological Disease
    5-HT1AR agonist 3 (Compound 77) is a 5-HT1A agonist. 5-HT1AR agonist 3 has 5-HT1A receptor agonist activity (EC50: 1.3 nM). 5-HT1AR agonist 3 mainly exerts its effects by activating 5-HT1A receptors and can be used in the study of neuropsychiatric diseases such as anxiety, depression and sleep disorders .
    5-HT1AR agonist 3
  • HY-162336
    Casein kinase 1δ-IN-15

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC50 of 0.045 μM .
    Casein kinase 1δ-IN-15
  • HY-103493R
    TAK-915 (Standard)

    		Reference Standards Phosphodiesterase (PDE) Neurological Disease
    TAK-915 (Standard) is the analytical standard of TAK-915 (HY-103493). This product is intended for research and analytical applications. TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .
    TAK-915 (Standard)
  • HY-182453
    RM1490

    		Opioid Receptor Neurological Disease
    RM1490 (Compound 251) acts as an inhibitor of μ-opioid receptor (MOR) (IC50 ≤ 300 nM), an activator of δ-opioid receptor (DOR) (EC50 > 3000 nM), and an inhibitor of κ-opioid receptor (KOR) (IC50 ≤ 300 nM). RM1490 is applicable to the research of neuropsychiatric disorders .
    RM1490
  • HY-W698445
    α-Nicotine

    		Drug Isomer nAChR Neurological Disease
    α-Nicotine is the α-isomer of Nicotine. Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist. Nicotine is promising for research of neuropsychiatric disorders (e.g., schizophrenia, ADHD) .
    α-Nicotine
  • HY-111241
    SV 293

    		Dopamine Receptor Neurological Disease
    SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders .
    SV 293
  • HY-179568
    F3288-0031

    		Monoamine Transporter Neurological Disease
    F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC50 = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions .
    F3288-0031
  • HY-182944
    GATT-44

    		GABA Receptor Neurological Disease
    GATT-44 is a blood-brain barrier-permeable, selective GABA transporter 1 (GAT-1) ligand with an IC50 of 126 nM. GATT-44 shows selectivity for GAT-2, GAT-3 and BGT-1 subtypes, and undergoes copper-mediated 18F-radiofluorination. The radiolabeled GATT-44 ([ 18F]GATT-44) exhibits brain uptake, metabolic stability and high GAT-1 binding specificity in non-human primates. GATT-44 is applicable for research on neurodegenerative and neuropsychiatric diseases .
    GATT-44
  • HY-181047
    FMJ-01-042

    		Dopamine Receptor Neurological Disease
    FMJ-01-042 is a blood-brain barrier-permeable, low-efficacy partial agonist with high affinity (Kᵢ = 4.33 nM) and exceptional subtype selectivity for the dopamine D4 receptor. FMJ-01-042 exhibits good metabolic stability and is suitable for research on neurological and psychiatric disorders .
    FMJ-01-042
  • HY-181613
    5-HT2A&5-HT2C agonist-3

    		5-HT Receptor Neurological Disease
    5-HT2A&5-HT2C agonist-3 (compound 4e) is an orally bioavailable and blood-brain barrier penetrant agonist of 5-HT2A and 5-HT2C. 5-HT2A&5-HT2C agonist-3 increases intracellular calcium levels in cells overexpressing 5-HT2A or 5-HT2C receptors, and shows no activity against 5-HT2B receptors. 5-HT2A&5-HT2C agonist-3 can be used for the research of neuropsychiatric disorders .
    5-HT2A&5-HT2C agonist-3

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: